================================================================================

                            SCHEDULE 14A INFORMATION
                   PROXY STATEMENT PURSUANT TO SECTION 14(a)
                     OF THE SECURITIES EXCHANGE ACT OF 1934


Filed by the Registrant [ ]
Filed by a Party other than the Registrant [X]
    Check the appropriate box:
     [ ]   Preliminary Proxy Statement
     [ ]   Confidential, for Use of the Commission only (as permitted by
           Rule 14a-6(e)(2))
     [ ]   Definitive Proxy Statement
     [ ]   Definitive Additional Materials
     [X]   Soliciting Material Under Rule 14a-12


                          NORTHFIELD LABORATORIES INC.

                (Name of Registrant as Specified in its Charter)

                                C. ROBERT COATES
                                ----------------

     (Name of Person(s) Filing Proxy Statement if other than the Registrant)


Payment of Filing Fee (Check the appropriate box):

[X]  No fee required.
[ ]  $125 per Exchange Act Rules 0-11(c)(1)(ii), 14a-6(i)(1), 14a-6(i)(2) or
     Item 22(a)(2) of Schedule 14A.
[ ]  Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
     1)     Title of each class of securities to which transaction applies:
     2)     Aggregate number of securities to which transaction applies:
     3)     Per unit price or other underlying value of transaction computed
            pursuant to Exchange Act Rule 0-11 (Set forth the amount on which
            the filing fee is calculated and state how it was determined):
     4)     Proposed maximum aggregate value of transaction:
     5)     Total fee
            paid:
[ ]  Fee paid previously with preliminary materials.
[ ]  Check box if any part of the fee is offset as provided by Exchange Act Rule
     0-11(a)(2) and identify the filing for which the offsetting fee was paid
     previously. Identify the previous filing by registration statement number,
     or the Form or Schedule and the date of its filing.
     1)     Amount Previously Paid:
     2)     Form, Schedule or Registration Statement No.:
     3)     Filing Party: C. Robert Coates
     4)     Date Filed: September 12, 2002

================================================================================

Press Release

SOURCE: C. Robert Coates

COATES, WILLIAMS TELL SHAREHOLDERS: ELECT US AND WE WILL SUPPORT BIERBAUM, NESS

LAKE  FOREST, Ill., Sept. 12 -- C. Robert Coates and Bert Williams,  independent
candidates   for  directorships  of  Northfield  Laboratories  (Nasdaq:   NFLD),
reiterated their "no-lose" proposition for shareholders: elect them to the board
and  still benefit from the services of John F. Bierbaum and Dr. Paul  M.  Ness,
the two Northfield-endorsed nominees.

"Our  first intention if we win the September 13 election is to expand the board
by  adding Bierbaum and Ness, a move expressly allowed by Northfield's  bylaws",
said Coates.

Coates  holds  a  4.5% stake in Northfield and has a background in  finance  and
management;  Williams  has extensive management, marketing  and  Food  and  Drug
Administration experience. Bierbaum is an executive of PepsiAmericas Inc., which
holds 10.5% of Northfield's stock and is its largest shareholder, while Ness  is
a professor of pathology at Johns Hopkins University.

"Northfield  has spent an enormous sum of time and money on this proxy  contest,
resources  that  might  more wisely have gone toward  getting  approval  of  its
stalled PolyHeme blood substitute", said Coates.

"The  company also has issued numerous press releases. We are happy to see  them
starting to communicate with investors, but we find the information they put out
contains little of substance. Shareholders still have no clear understanding  of
where  Northfield  is  in the FDA process or how long the  company  can  survive
without getting PolyHeme approved", Coates added.

As  shareholder  advocates, Coates and Williams have  vowed  to  keep  investors
informed  of  Northfield news, something that will be much  easier  with  direct
access  to  information  on the board of directors. They  also  will  work  with
directors  and  management to advance Northfield's efforts in  finding  a  major
pharmaceutical company to invest money and talent in Northfield and in advancing
PolyHeme to commercialization. Their goal remains to improve performance of  the
company's underperforming shares in the market.

Contact Information

If you are a shareholder with comments, suggestions or questions about the Sept.
13 proxy contest, please call Simon Goldberg of the Robert Coates Group at 1-800
-295-0841, extension 240, or e-mail us at sgoldberg@rcoates.com .

SOURCE: C. Robert Coates